No annual revenue total was found in PROPANC BIOPHARMA, INC.'s SEC filings.
Propanc Biopharma, Inc. (PPCB) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$5.7 million. As of Jun 30, 2026 it held $832,006 in cash and investments and $48,307 in total debt.
Revenue
—
Net income
$-18.86M
+68.0% vs prior year
Operating cash flow
$-5.68M
-1302.5% vs prior year
Free cash flow
$-5.69M
-175.7% vs prior year
EPS
$-17.62
+95.3% vs prior year
Dividend per share
None
Shares outstanding
6.33M
-50.6% vs prior year
Net cash
$783,699
FY 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PPCB (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Camberwell, Victoria, Australia
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1517681
- Former names
- Propanc Health Group Corp (until Apr 5, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Jun 30, 2026 |
FY 2025 Jun 30, 2025 |
FY 2024 Jun 30, 2024 |
FY 2023 Jun 30, 2023 |
FY 2022 Jun 30, 2022 |
|---|---|---|---|---|---|
| Operating income | -$18.2M | -$57.3M | -$1.5M | -$1.8M | -$2.0M |
| Net income | -$18.9M | -$58.9M | -$1.8M | -$2.7M | -$2.7M |
| Diluted EPS | -$17.62 | -$371.22 | -$1,420.53 | -$1.80 | — |
| Operating cash flow | -$5.7M | -$405,168 | -$935,118 | -$1.1M | -$1.4M |
| Free cash flow | -$5.7M | — | — | — | — |
| Total assets | $12.8M | $19.6M | $72,365 | $60,328 | $81,651 |
| Total liabilities | $3.4M | $5.7M | $3.9M | $3.2M | $3.1M |
| Stockholders' equity | $9.4M | $13.9M | -$3.8M | -$3.1M | -$3.0M |
| Cash and investments | $832,006 | $12,088 | $21,085 | $10,047 | — |
| Total debt | $48,307 | $537,921 | $399,325 | $390,539 | $989,362 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice
|
Oct 29, 2026 | Oct 23, 2026 |
| 10-K | Annual report | Sep 25, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 14, 2026 | Jul 8, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Officer or director change
|
Feb 26, 2026 | Feb 20, 2026 |
| 10-Q | Quarterly report | Feb 17, 2026 | Dec 31, 2025 |
All 438 Propanc Biopharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.